LON:SALV

SalvaRx Group Competitors

GBX 4.50
0.00 (0.00 %)
(As of 12/19/2019)
Add
Compare
Today's Range
4.50
Now: GBX 4.50
7.90
50-Day Range
4.50
MA: GBX 4.50
4.50
52-Week Range
4.50
Now: GBX 4.50
7.90
Volume50,758 shs
Average Volume50,758 shs
Market Capitalization£1.65 million
P/E Ratio0.03
Dividend YieldN/A
BetaN/A

Competitors

SalvaRx Group (LON:SALV) Vs. GNS, BTG, ABC, PRTC, OXB, and ERGO

Should you be buying SALV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to SalvaRx Group, including Genus (GNS), BTG (BTG), Abcam (ABC), PureTech Health (PRTC), Oxford Biomedica (OXB), and Ergomed (ERGO).

Genus (LON:GNS) and SalvaRx Group (LON:SALV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Genus and SalvaRx Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genus01102.50
SalvaRx Group0000N/A

Genus presently has a consensus target price of GBX 4,760, indicating a potential downside of 9.33%. Given Genus' higher possible upside, analysts clearly believe Genus is more favorable than SalvaRx Group.

Profitability

This table compares Genus and SalvaRx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenusN/AN/AN/A
SalvaRx GroupN/AN/AN/A

Earnings & Valuation

This table compares Genus and SalvaRx Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genus£566.40 million6.07N/AGBX 73.6071.54
SalvaRx Group£64.50 million0.03N/AGBX 168.800.03

SalvaRx Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Summary

Genus beats SalvaRx Group on 5 of the 6 factors compared between the two stocks.

BTG (LON:BTG) and SalvaRx Group (LON:SALV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for BTG and SalvaRx Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BTG0000N/A
SalvaRx Group0000N/A

Earnings & Valuation

This table compares BTG and SalvaRx Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£914.10 million3.57N/AGBX 28.5029.47
SalvaRx Group£64.50 million0.03N/AGBX 168.800.03

SalvaRx Group is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BTG and SalvaRx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BTGN/AN/AN/A
SalvaRx GroupN/AN/AN/A

Summary

BTG beats SalvaRx Group on 3 of the 4 factors compared between the two stocks.

SalvaRx Group (LON:SALV) and Abcam (LON:ABC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Earnings & Valuation

This table compares SalvaRx Group and Abcam's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SalvaRx Group£64.50 million0.03N/AGBX 168.800.03
Abcam£269.30 million12.09N/AGBX (0.90)-1,595.56

Abcam is trading at a lower price-to-earnings ratio than SalvaRx Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for SalvaRx Group and Abcam, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SalvaRx Group0000N/A
Abcam05102.17

Abcam has a consensus price target of GBX 1,378.33, suggesting a potential downside of 4.08%. Given Abcam's higher possible upside, analysts plainly believe Abcam is more favorable than SalvaRx Group.

Profitability

This table compares SalvaRx Group and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SalvaRx GroupN/AN/AN/A
AbcamN/AN/AN/A

Summary

Abcam beats SalvaRx Group on 4 of the 6 factors compared between the two stocks.

SalvaRx Group (LON:SALV) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Earnings and Valuation

This table compares SalvaRx Group and PureTech Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SalvaRx Group£64.50 million0.03N/AGBX 168.800.03
PureTech Health£12.26 million96.63N/AGBX 115.503.59

SalvaRx Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SalvaRx Group and PureTech Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SalvaRx GroupN/AN/AN/A
PureTech HealthN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SalvaRx Group and PureTech Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SalvaRx Group0000N/A
PureTech Health00403.00

PureTech Health has a consensus price target of GBX 481.25, suggesting a potential upside of 16.03%. Given PureTech Health's higher possible upside, analysts plainly believe PureTech Health is more favorable than SalvaRx Group.

Summary

PureTech Health beats SalvaRx Group on 4 of the 6 factors compared between the two stocks.

Oxford Biomedica (LON:OXB) and SalvaRx Group (LON:SALV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Oxford Biomedica and SalvaRx Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£65.94 million13.15N/AGBX (16.40)-64.15
SalvaRx Group£64.50 million0.03N/AGBX 168.800.03

Oxford Biomedica is trading at a lower price-to-earnings ratio than SalvaRx Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Oxford Biomedica and SalvaRx Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oxford Biomedica01202.67
SalvaRx Group0000N/A

Oxford Biomedica currently has a consensus target price of GBX 926.67, suggesting a potential downside of 11.85%. Given Oxford Biomedica's higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than SalvaRx Group.

Profitability

This table compares Oxford Biomedica and SalvaRx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oxford BiomedicaN/AN/AN/A
SalvaRx GroupN/AN/AN/A

Summary

Oxford Biomedica beats SalvaRx Group on 4 of the 6 factors compared between the two stocks.

Ergomed (LON:ERGO) and SalvaRx Group (LON:SALV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Profitability

This table compares Ergomed and SalvaRx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ErgomedN/AN/AN/A
SalvaRx GroupN/AN/AN/A

Earnings and Valuation

This table compares Ergomed and SalvaRx Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed£86.39 million6.01N/AGBX 19.2055.49
SalvaRx Group£64.50 million0.03N/AGBX 168.800.03

SalvaRx Group is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Ergomed and SalvaRx Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ergomed0000N/A
SalvaRx Group0000N/A

Summary

Ergomed beats SalvaRx Group on 3 of the 4 factors compared between the two stocks.


SalvaRx Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Genus logo
GNS
Genus
1.3$5,265.00flat£3.38 billion£566.40 million71.54Gap Down
BTG logo
BTG
BTG
0.7$840.00flat£3.26 billion£914.10 million29.47
Abcam logo
ABC
Abcam
0.5$1,436.00flat£3.23 billion£269.30 million-1,595.56Gap Down
PureTech Health logo
PRTC
PureTech Health
1.5$414.50flat£1.18 billion£12.26 million3.59Upcoming Earnings
Gap Up
Oxford Biomedica logo
OXB
Oxford Biomedica
0.8$1,052.00flat£857.01 million£65.94 million-64.15Upcoming Earnings
Ergomed logo
ERGO
Ergomed
0.6$1,065.50flat£567.94 million£86.39 million55.49Gap Up
Silence Therapeutics logo
SLN
Silence Therapeutics
0.9$548.71flat£476.50 million£5.48 million-13.79
Synairgen logo
SNG
Synairgen
0.4$152.30flat£304.47 million£79,000.00-29.86
NCYT
Novacyt
0.6$409.00flat£300.09 million£78.23 million7.90
ORPH
Open Orphan
0.0$44.45flat£297.88 million£10.57 million-13.89
ARIX
Arix Bioscience
0.8$189.70flat£255.45 million£135.77 million2.14
Bioventix logo
BVXP
Bioventix
0.8$4,075.00flat£212.53 million£10.38 million31.06
DDDD
4D pharma
0.6$113.41flat£202.97 million£690,000.00-5.85
Scancell logo
SCLP
Scancell
0.6$22.65flat£187.50 millionN/A-16.18
Tiziana Life Sciences logo
TILS
Tiziana Life Sciences
0.4$93.50flat£184.88 millionN/A-17.00
Redx Pharma logo
REDX
Redx Pharma
0.6$67.25flat£184.87 million£5.69 million-12.45
Faron Pharmaceuticals Oy logo
FARN
Faron Pharmaceuticals Oy
0.6$335.10flat£171.42 million£2.12 million-10.44
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50flat£138.87 millionN/A-0.21Gap Up
ANIC
Agronomics
0.5$25.53flat£137.32 million£1.05 million-127.65
VSN
Verseon
0.5$74.00flat£127.41 millionN/A-5.17Gap Down
Circassia Group logo
CIR
Circassia Group
0.9$29.01flat£120.50 million£23.90 million-3.30Gap Down
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$55.00flat£108.07 millionN/A-1.68News Coverage
Gap Down
SBTX
SkinBioTherapeutics
0.4$70.96flat£101.91 millionN/A-70.96
Destiny Pharma logo
DEST
Destiny Pharma
0.5$173.90flat£98.73 million£305,906.00-15.12News Coverage
Gap Down
C4XD
C4X Discovery
0.6$40.59flat£93.93 million£7.06 million-5.01
ETX
e-therapeutics
0.4$20.03flat£86.05 million£305,000.00-20.03Gap Down
OBD
Oxford BioDynamics
0.5$83.00flat£80.53 million£456,000.00-17.66
ReNeuron Group logo
RENE
ReNeuron Group
0.6$131.25flat£80.17 million£112,000.00-2.86
OKYO
OKYO Pharma
0.5$7.65flat£51.47 millionN/A-76.50Gap Up
OptiBiotix Health logo
OPTI
OptiBiotix Health
0.4$51.28flat£44.41 million£687,584.00-22.30
Tissue Regenix Group logo
TRX
Tissue Regenix Group
0.5$0.62flat£43.96 million£13.05 million-1.55
HVO
Hvivo
0.5$16.50flat£43.33 million£12.09 million-0.83
4BB
4basebio UK Societas
0.3$330.00flat£41.26 millionN/A0.00Gap Up
FAB
Fusion Antibodies
0.5$147.42flat£38.93 million£4.05 million-49.14
IXICO logo
IXI
IXICO
1.0$73.35flat£35.26 million£9.53 million36.68
RUA
Rua Life Sciences
0.0$146.48flat£34.39 million£835,000.00-17.86
COS
Collagen Solutions plc (COS.L)
0.6$6.63flat£28.43 million£4.01 million-8.28
ImmuPharma logo
IMM
ImmuPharma
0.6$9.46flat£23.90 million£128,395.00-3.15News Coverage
AOR
AorTech International
0.5$123.50flat£21.85 million£539,000.00-33.38
HEMO
Hemogenyx Pharmaceuticals
0.4$4.29flat£20.00 millionN/A-10.73High Trading Volume
News Coverage
Gap Down
Midatech Pharma logo
MTPH
Midatech Pharma
0.7$31.00flat£19.65 million£390,000.00-0.33Gap Up
NFX
Nuformix
0.5$2.24flat£14.20 million£195,550.00-11.18Gap Up
RLM
Realm Therapeutics
0.7$11.50flat£13.41 million£501,919.00-0.66
ValiRx logo
VAL
ValiRx
0.7$19.60flat£13.34 millionN/A-1.09News Coverage
OVB
Ovoca Bio
0.7$11.50flat£10.17 millionN/A-2.30Gap Up
NSCI
NetScientific
0.5$64.00flat£9.54 million£394,000.00-22.07News Coverage
Horizon Discovery Group plc (HZD.L) logo
HZD
Horizon Discovery Group plc (HZD.L)
0.8$184.50flat£8.23 million£54.63 million-33.55News Coverage
Gap Down
PYC
Physiomics
0.4$6.82flat£6.96 million£884,649.00-68.23
Motif Bio logo
MTFB
Motif Bio
0.6$0.50flat£3.28 millionN/A-0.18
PEBI
Port Erin Biopharma Investments
0.6$4.50flat£1.04 million£28,300.00-6.43Gap Down
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.